Evidence map›Paper›PMID 40965814›Full record

ArticleStem cell reviews and reports2025

Dimethyl Sulfoxide Conditions Induced Pluripotent Stem Cells for more Efficient Nephron Progenitor and Kidney Organoid Differentiation.

Helen Kearney, Aleksandra Rak-Raszewska, Adrián Seijas-Gamardo, Enrique Escarda-Castro, Florian Caiment, Paul Wieringa, Lorenzo Moroni, Carlos Mota

Abstract read
In one paragraph

Article in Stem cell reviews and reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Helen KearneyMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0009-0007-9901-3221
Aleksandra Rak-RaszewskaMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0002-2399-4410
Adrián Seijas-GamardoMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0002-8950-367X
Enrique Escarda-CastroMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0001-6661-9963
Florian CaimentTranslational Genomics, GROW Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0002-3325-0466
Paul WieringaMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0002-3290-5125
Lorenzo MoroniMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands.ORCID 0000-0003-1298-6025
Carlos MotaMERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Maastricht, 6229 ER, the Netherlands. c.mota@maastrichtuniversity.nl.ORCID 0000-0001-5935-6245

Funding

H2020 Future and Emerging Technologies 964452H2020 Marie Skłodowska-Curie Actions 860715HORIZON EUROPE Marie Sklodowska-Curie Actions 101106539
6 · The paper itself

Abstract

The field of human induced pluripotent stem cells (hiPSCs) has seen significant progress since the discovery of reprogramming somatic cells using the transcription factors Oct4, Sox2, Klf4, and c-Myc. hiPSCs are similar to embryonic stem cells in a primed state of pluripotency and have the potential to differentiate into any adult human cell type, offering a versatile tool for research and potential therapeutic applications. However, the efficiency of differentiation protocols for generating complex structures with multiple cell types, Like kidney organoids, remains a challenge. This study investigates the impact of treating hiPSCs with a low-dose dimethyl sulfoxide to enhance kidney organoid differentiation using the stepwise 2D monolayer-based protocol developed by Morizane et al. 2017. We found that treating hiPSCs with 1-2% DMSO affects gene expression of pluripotent transcription factors, the epigenetic landscape, and hiPSC colony morphology. Our findings also suggest DMSO treatment enhances the expression of the key metanephric mesenchyme nephron progenitor marker, SIX2 after 9 days of kidney organoid differentiation and helps improve hiPSC differentiation protocol efficiency toward the development of tubular kidney organoids. Further research is needed to fully elucidate the mechanisms underlying these effects and refine the differentiation process for potential in vitro research applications in biomedical research and drug development.

Indexed as

Cell DifferentiationDimethyl SulfoxideInduced Pluripotent Stem CellsKidneyNephronsOrganoidsHomeodomain ProteinsHumansKruppel-Like Factor 4Nerve Tissue ProteinsTranscription FactorsDimethyl SulfoxideHomeodomain ProteinsKLF4 protein, humanKruppel-Like Factor 4Nerve Tissue ProteinsSIX2 protein, humanTranscription FactorsDifferentiation potentialDifferentiation protocol efficiencyDimethyl sulfoxideInduced-pluripotent stem cellsKidney organoidsNephron progenitor cells

Identifiers

PMID40965814
PMCPMC12504399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.